At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ASLN ASLAN PHARMACEUTICALS LIMITED SPON ADS EACH REP 25 ORD SHS (P/S)
Not Yet Opened 12-20 16:00:00 EST
0.6000
+0.0000
0.00%
High0.6000
Low0.6000
Vol0.00
Open0.6000
D1 Closing0.6000
Amplitude0.00%
Mkt Cap1.70M
Tradable Cap1.49M
Total Shares2.83M
T/O0.00
T/O Rate0.00%
Tradable Shares2.49M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Asian Equities Traded in the US as American Depositary Receipts Plummet in Monday Trading
Press Release: ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation
ASLAN PHARMACEUTICALS LIMITED SPON ADS EACH REP 25 ORD SHS (P/S)
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.